Summary
DexCom, Inc. (DXCM) filed its Form 10-Q for the quarterly period ended September 30, 2010, on November 4, 2010. The filing highlights the company's continued focus on its continuous glucose monitoring (CGM) systems, specifically the SEVEN PLUS. While product revenue showed significant year-over-year growth, driven by increased sales volume, the company also reported substantial operating losses and an accumulated deficit. Key financial activities during the period included the conversion of all outstanding convertible senior notes, which eliminated long-term debt but resulted in a significant loss on extinguishment. The company also successfully completed a follow-on public stock offering in January 2010, raising approximately $33.0 million. Despite these capital-raising efforts, DexCom anticipates continued losses in the foreseeable future due to ongoing investments in research and development, sales, and marketing activities. Management believes current cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next twelve months, but potential future capital needs remain a consideration.
Financial Highlights
22 data points| Revenue | $11.66M |
| Cost of Revenue | $8.19M |
| Gross Profit | $3.48M |
| R&D Expenses | $6.16M |
| SG&A Expenses | $10.38M |
| Operating Expenses | $16.54M |
| Operating Income | -$13.06M |
| Interest Expense | $44K |
| Net Income | -$13.40M |
| EPS (Basic) | $-0.06 |
Key Highlights
- 1Product revenue increased significantly by 133% to $10.8 million for the three months ended September 30, 2010, compared to $4.6 million in the prior year period, driven by higher sales volume.
- 2Despite the revenue growth, the company reported a net loss of $13.4 million for the third quarter of 2010, compared to a net loss of $13.5 million in the prior year period.
- 3All outstanding 4.75% Convertible Senior Notes due in 2027 were converted into common stock during the nine months ended September 30, 2010, eliminating the company's long-term debt.
- 4A loss on extinguishment of convertible debt of $8.5 million was recorded for the nine months ended September 30, 2010, due to the conversion of these notes.
- 5The company raised $33.0 million in net proceeds from a follow-on public stock offering in January 2010.
- 6Research and development expenses increased by 74% to $6.2 million for the third quarter of 2010, reflecting increased development efforts for ambulatory products.
- 7Selling, general, and administrative expenses increased by 16% to $10.4 million for the third quarter of 2010, supporting revenue growth and product commercialization.